Navigation Links
Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
Date:12/10/2009

TARRYTOWN, N.Y., Dec. 10 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Deutsche Bank 2009 Biotech Boston Confab on Tuesday, December 15, 2009. The presentation is scheduled for 3:35 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through January 15, 2010. Additional information about Regeneron and recent news releases are available on the Regeneron web site.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.


Contact Information:

Peter Dworkin                  Laura Lindsay
Investor Relations             Media Relations
914.345.7640                   914.345.7800
peter.dworkin@regeneron.com    laura.lindsay@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Iowa , Jan. 18, 2017   ... that subsidiary Caretta Therapeutics plans, in the second ... Venodol, a topical roll-on intended to provide relief ... opioid and steroidal analgesics. It was developed under ... to commercialize products derived from snake venom. ...
(Date:1/18/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, announces dosing the first patient ... 2 acne rosacea study. DMT210 is a topical ... in the skin responsible for the inflammation and ... This clinical trial, DMT210-003, is a 12-week, Phase ...
(Date:1/18/2017)... Jan. 17, 2017  With an annual growth ranging from 6% to 10%, ... SEA (Jakarta International Expo, March 22-24, 2017) serves the industry by fostering the ... CPhI SEA 2017? Investment Forum ASEAN -- ... Richer conference content Enhanced business matchmaking program ... ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their commitment ... they have achieved certification to ISO 13485. This certification is another way they are ... date products and services that they need. , The ISO 13485 Certification is a ...
(Date:1/18/2017)... NJ (PRWEB) , ... January 18, 2017 , ... ... care communications company, launched a new website for its Center for Biosimilars, announced ... will include the latest developments in the field of biosimilars through thought leader ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... gum disease to enamel erosion, and those dental problems can increase the risk ... Health, many pregnant women are failing to get the dental care they need. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress ... dentists to choose the best drug option for each patient. Dentists have several general ... better overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted ...
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
Breaking Medicine News(10 mins):